Page last updated: 2024-09-03

clofarabine and cytarabine

clofarabine has been researched along with cytarabine in 98 studies

Compound Research Comparison

Studies
(clofarabine)
Trials
(clofarabine)
Recent Studies (post-2010)
(clofarabine)
Studies
(cytarabine)
Trials
(cytarabine)
Recent Studies (post-2010) (cytarabine)
42410128015,4872,4243,188

Protein Interaction Comparison

ProteinTaxonomyclofarabine (IC50)cytarabine (IC50)
nuclear receptor coactivator 3 isoform aHomo sapiens (human)7.533
E3 ubiquitin-protein ligase Mdm2Homo sapiens (human)0.02

Research

Studies (98)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (2.04)18.2507
2000's15 (15.31)29.6817
2010's74 (75.51)24.3611
2020's7 (7.14)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Albertioni, F; Eriksson, S; Hullán, L; Sasvári-Székely, M; Spasokoukotskaja, T; Staub, M1
Albertioni, F; Larsson, BS; Liliemark, J; Lindemalm, S1
Estey, EH; Thall, PF1
Beran, M; Bonate, P; Cortes, J; Du, M; Estey, E; Estrov, Z; Faderl, S; Ferrajoli, A; Gandhi, V; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Keating, M; Kwari, M; O'Brien, S; Plunkett, W; Wierda, W1
Cooper, T; Gandhi, V; Kantarjian, H; Plunkett, W1
Ayres, M; Cooper, T; Gandhi, V; Nowak, B1
Beran, M; Cortes, J; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Koller, C; Kwari, M; O'Brien, S; Ravandi, F; Verstovsek, S; Wierda, W1
Gidwani, P; Kolb, EA; Liu, Y; Ramesh, KH1
Craig, CM; Schiller, GJ1
Borthakur, G; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Huang, X; Kantarjian, HM; Kwari, M; Ravandi, F; Thomas, DA; Verstovsek, S1
Borthakur, G; Estrov, Z; Faderl, S; Ferrajoli, A; Huang, X; Kantarjian, HM; Kwari, M; Ravandi, F; Verstovsek, S; Wierda, W1
Abboud, CN; Augustin, K; Cashen, A; DiPersio, JF; Luo, J; Martin, MG; Procknow, E; Stockerl-Goldstein, K; Uy, GL; Vij, R; Westervelt, P1
Tallman, M1
Brown, AW; McGregor, BA; Osswald, MB; Savona, MR1
Baccarani, M; Cilloni, D; Curti, A; Derenzini, E; Iacobucci, I; Martinelli, G; Paolini, S; Papayannidis, C1
Einsele, H; Grigoleit, GU; Kapp, M; Mielke, S; Stuhler, G; Tan, SM; Topp, MS; Unzicker, C1
Faderl, S1
Cutlan, JE; Geddes, ER; Hymes, SR; Polder, K; Torres-Cabala, CA1
Faderl, S; Ghandhi, V; Ghanem, H; Jabbour, E; Kantarjian, H; Plunkett, W1
Advani, AS; Appelbaum, FR; Coutre, SE; Gundacker, HM; Lai, R; Lancet, JE; Mims, MP; Radich, JP; Sala-Torra, O; Slovak, ML; Stiff, PJ; Stuart, RK1
Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A1
Agura, E; Berryman, RB; Cooper, B; Fay, J; Holmes, H; Li, S; Maisel, C; Saracino, G; Tadic-Ovcina, M; Vance, E1
Chastagner, P; Clement, L; Contet, A; Kimmoun, A; Salmon, A; Schmitt, C; Sudour, H1
Kwong, YL; Lee, HK; Leung, AY; Liu, HS; Sim, J; Tse, E; Yip, SF1
Appelbaum, FR; Becker, P; Estey, E; Hendrie, P; Knoebel, RW; McQuary, A; Petersdorf, S1
Bautista, F; Del Mar Andres, M; Fernandez-Navarro, JM; Moreno, L; Tasso, M; Verdeguer, A1
Burnett, AK; Hills, RK1
Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA1
Beutel, G; Buchholz, S; Dammann, E; Eder, M; Ganser, A; Krauter, J; Stadler, M; Trummer, A1
Borthakur, G; Burger, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Ravandi, F; Wang, X1
Fukuda, Y; Schuetz, JD1
Campbell, DO; Czernin, J; Lee, JT; Radu, CG; Satyamurthy, N1
Arceci, RJ; Barry, E; Hijiya, N1
Barba, P; Bueno, J; Calbacho, M; Fernández, P; García-Boyero, R; Gonzalez, J; Martínez-Sánchez, P; Ribera, JM; Sampol, A; Serrano, J1
Buck, SA; Edwards, H; Ge, Y; Lograsso, SB; Matherly, LH; Taub, JW; Xie, C1
Avigan, D; Collins, R; Craig, M; Faderl, S; Ganguly, S; Goldberg, S; Greiner, J; Hari, P; Huebner, D; Jagasia, M; Kantarjian, HM; Kovacsovics, T; Maris, M; Ravandi, F; Recher, C; Rizzieri, D; Schiller, G; Seiter, K; Stuart, R; Vasconcelles, M; Vey, N; Wang, ES; Wetzler, M1
Goozner, M1
Appelbaum, FR; Becker, PS; Estey, EH; Faderl, S; Kantarjian, HM; Pierce, S; Shan, J; Storer, B1
Burnett, AK; Craddock, CF; Dufva, IH; Freeman, S; Hills, RK; Hunter, AE; Kell, J; Kjeldsen, L; Milligan, D; Russell, NH; Wheatley, K; Yin, J1
Hwang, YY; Kwong, YL; Trendell-Smith, NJ; Yeung, CK1
Angelucci, E; Biagiotti, C; Borin, L; Bosi, A; Caracciolo, F; Cutini, I; Fanci, R; Gianfaldoni, G; Longo, G; Mannelli, F; Pogliani, EM; Romani, C; Scappini, B; Simonetti, F; Susini, MC1
Adlard, K; Alonzo, TA; Cooper, TM; Gamis, AS; Gerbing, R; Perentesis, J; Raetz, E; Razzouk, BI; Whitlock, JA1
Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A1
Ali, S; Bowen, D; Burnett, AK; Hills, RK; Hunter, AE; Knapper, S; McMullin, MF; Milligan, D; Russell, NH; Wheatley, K; Yin, J1
Andreeff, M; Borthakur, G; Brandt, M; Choi, S; Cortes, J; Daver, N; Du, M; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; Kornblau, S; Nazha, A; Pemmaraju, N; Ravandi, F1
Bergua, J; Carpio, C; Herrera, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Oriol, A; Rodríguez-Veiga, R; Salamero, O; Sanz, J; Sanz, MA; Vidriales, B; Vives, S1
Azzarà, A; Benedetti, E; Buda, G; Caracciolo, F; Carulli, G; Fontanelli, G; Galimberti, S; Orciuolo, E; Petrini, M; Rocco, M1
Bryan, J; Jabbour, E; Kantarjian, H; Prescott, H1
Advani, AS; Appelbaum, FR; Becker, M; Coutre, S; Elkins, S; McDonough, S; Mims, M; O'Donnell, M; Othus, M; Radich, J; Wood, B1
Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R1
Nishi, R; Shigemi, H; Ueda, T; Uzui, K; Yamauchi, T1
Alonzo, TA; Cooper, TM; Gamis, AS; Gerbing, RB; Horton, TM; Loken, MR; Meshinchi, S; Perentesis, JP; Razzouk, BI; Taub, JW; Whitlock, JA1
Wiernik, PH1
Bolognia, J; Marks, P; Podoltsev, N; Zhang, B1
Fozza, C1
Abkowitz, JL; Appelbaum, FR; Becker, PS; Estey, EH; Forman, SJ; Gardner, KM; Hendrie, PC; Medeiros, BC; Othus, M; Pagel, JM; Parks, C; Scott, BL; Stein, AS; Walter, RB; Wood, BL1
Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Wang, X1
Allen, CE; Ladisch, S; McClain, KL1
Becker, PS; Buckley, SA; Dean, C; Estey, EH; Gooley, TA; Hendrie, P; Mawad, R; Pagel, JM; Sandhu, V; Scott, BL; Smith, K; Walter, RB; Wood, BL1
Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D1
Pieters, R; Schneider, P; Stam, RW; Stumpel, DJ1
Alousi, A; Anderlini, P; Andersson, BS; Borthakur, G; Bueso-Ramos, C; Champlin, RE; Chen, J; Ciurea, SO; El Fakih, R; Gaballa, S; Garcia-Manero, G; Hosing, C; Jimenez, A; Kantarjian, H; Kebriaei, P; Khouri, IF; Kongtim, P; Marin, D; Oran, B; Pemmaraju, N; Popat, U; Rezvani, K; Rondon, G; Shpall, EJ1
Andreeff, M; Borthakur, G; Cortes, J; DiNardo, C; Estrov, Z; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Takahashi, K1
Goto, H; Goto, S; Yokosuka, T1
Bornhäuser, M; Büttner, B; Knoth, H; Middeke, JM; Oertel, R; Schetelig, J; Seeling, A1
Gerber, JM; Grunwald, MR; Induru, R; McDonnell, MH1
Appelbaum, FR; Becker, PS; Bernstein, ID; Cicconi, L; Dahlberg, A; Delaney, C; Estey, EH; Milano, F; Nicoud, I; Othus, M; Sandhu, V1
Ali, S; Burnett, AK; Burns, S; Cahalin, P; Clark, RE; Dennis, M; Freeman, S; Hills, RK; Kell, J; Milligan, D; Nielsen, OJ; Pocock, C; Russell, NH1
Bohannan, Z; Borthakur, G; Bueso-Ramos, C; Daver, N; Faderl, S; Garcia-Manero, G; Hosing, C; Jabbour, E; Kadia, T; Kantarjian, HM; Khoury, JD; Maduike, R; Miller, D; Patel, K; Pemmaraju, N; Ravandi, F; Sasaki, K; Verstovsek, S1
Amadori, S; Baron, F; de Witte, T; Halkes, CJ; Marie, JP; Meert, L; Meloni, G; Muus, P; Pruijt, H; Ramadan, SM; Selleslag, D; Suciu, S; Venditti, A; Vignetti, M; Willemze, R; Wittnebel, S1
Berthon, C; Cahn, JY; Caillot, D; Castaigne, S; Celli-Lebras, K; Chevret, S; de Botton, S; Dombret, H; Hermine, O; Ifrah, N; Lemasle, E; Marolleau, JP; Pigneux, A; Preudhomme, C; Raffoux, E; Recher, C; Reman, O; Simon, M; Terré, C; Thomas, X; Vey, N1
Brower, V1
Borthakur, G; Brandt, M; Cortes, JE; Daver, NG; DiNardo, CD; Estrov, Z; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Konopleva, M; O'Brien, SM; Pemmaraju, N; Plunkett, W; Ravandi, F; Sasaki, K; Short, NJ; Wierda, WG; Xiao, L2
Isaac McGraw, B; Savaşan, S; Sweeney, C1
Damiani, D; Fanin, R; Michelutti, A; Tiribelli, M1
Altuntaş, F; Ayyildiz, MO; Bekdemir, F; Çakar, MK; Dal, MS; Dogu, MH; Hacioglu, SK; Ilkkiliç, K; Karakus, A; Kaya, AH; Korkmaz, S; Merdin, A; Tekgündüz, E1
Bixby, DL; Crouch, A; Marini, BL; Nachar, VR; Perissinotti, AJ; Scappaticci, GB; Talpaz, M; Uebel, JR; Vulaj, V1
Bejanyan, N; Defor, T; Eckfeldt, C; He, F; Kurtzweil, A; Parker, S; Rashidi, A; Sapkota, S; Ustun, C; Warlick, E; Weisdorf, D1
Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J1
Ali, A; Burnett, AK; Cahalin, P; Freeman, S; Hills, RK; Hunter, A; Nielsen, OJ; Russell, NH; Thomas, IF1
Becker, H; Döhner, H; Döhner, K; Fiedler, W; Gaidzik, VI; Ganser, A; Götze, KS; Greil, C; Heuser, M; Janning, M; Kebenko, M; Könecke, C; Krauter, J; Lübbert, M; Neuhaus, B; Papkalla, A; Paschka, P; Reimer, P; Schlenk, RF; Thol, F; Verbeek, M; Wattad, M1
Bridges, AG; El-Azhary, RA; Hashmi, SK; Hunjan, MK; Lehman, JS; Nowsheen, S; Ramos-Rodriguez, AJ1
Alary, AS; Bouscary, D; Deau, B; Fontenay, M; Hermine, O; Kosmider, O; Mondesir, J; Sibon, D; Suarez, F; Tamburini, J; Willems, L1
Stirrups, R1
Cumpston, A; Kanate, AS; Vos, J; Walchack, R1
Akhter, N; Altman, JK; Canaani, J; Cascino, GJ; Foran, JM; Furiasse, N; Ky, B; Litzow, MR; Luger, S; Rademaker, A; Rigolin, V; Tallman, MS; Voss, WB1
An, HY; Choi, HJ; Choi, JY; Hong, KT; Kang, HJ; Kim, BK; Shin, HY1
Rajamani, A; Ramasamy, S; Saravanan, V; Subramani, M1
Hosono, N; Negoro, E; Nishi, R; Okura, M; Shigemi, H; Yamauchi, T1
Gulati, N1
Borthakur, G; Burger, J; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Pemmaraju, N; Pierce, S; Popat, U; Rausch, C; Ravandi, F; Verstovsek, S; Wang, X1
Borkhardt, A; Dilloo, D; Escherich, G; Faber, J; Feuchtinger, T; Horstmann, MA; Imschweiler, T; Jorch, N; Pekrun, A; Schmid, I; Schramm, F; Spohn, M; Zimmermann, M; Zur Stadt, U1
Ali, S; Burnett, AK; Cahalin, P; Clark, RE; Hills, RK; Kjeldsen, L; Russell, NH; Thomas, IF1

Reviews

12 review(s) available for clofarabine and cytarabine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
    Blood reviews, 2008, Volume: 22, Issue:4

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides

2008
The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
    American journal of hematology, 2009, Volume: 84, Issue:4

    Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Etoposide; Fatal Outcome; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Mitoxantrone; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Remission Induction; Reoperation; Salvage Therapy; Vidarabine; Vincristine; Young Adult

2009
Clofarabine in leukemia.
    Expert review of hematology, 2010, Volume: 3, Issue:1

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cytarabine; Drug Therapy, Combination; Humans; Leukemia; Lymphoproliferative Disorders

2010
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
    Current medicinal chemistry, 2011, Volume: 18, Issue:5

    Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1

2011
ABC transporters and their role in nucleoside and nucleotide drug resistance.
    Biochemical pharmacology, 2012, Apr-15, Volume: 83, Issue:8

    Topics: Adenine Nucleotides; Arabinonucleosides; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cladribine; Clofarabine; Cytarabine; Drug Resistance; Humans; Neoplasm Proteins; Nucleosides; Nucleotides; Polymorphism, Single Nucleotide

2012
Clofarabine in pediatric acute leukemia: current findings and issues.
    Pediatric blood & cancer, 2012, Volume: 59, Issue:3

    Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clinical Trials as Topic; Clofarabine; Cyclophosphamide; Cytarabine; Etoposide; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma

2012
Clofarabine in the treatment of myelodysplastic syndromes.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:2

    Topics: Adenine Nucleotides; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Cytarabine; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Myelodysplastic Syndromes

2014
Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.
    Current treatment options in oncology, 2014, Volume: 15, Issue:2

    Topics: Adenine Nucleotides; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Humans; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome; Young Adult

2014
The role of Clofarabine in the treatment of adults with acute myeloid leukemia.
    Critical reviews in oncology/hematology, 2015, Volume: 93, Issue:3

    Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome

2015
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:3

    Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hemorrhage; Humans; Hypertension; Indoles; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Niacinamide; Pain; Pancytopenia; Phenylurea Compounds; Protease Inhibitors; Pyrroles; Salvage Therapy; Sepsis; Sorafenib; Sunitinib

2015
Cutaneous manifestations in leukemia patients.
    Seminars in oncology, 2016, Volume: 43, Issue:3

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dermatomycoses; Etoposide; Humans; Leukemia; Mastocytosis; Niacinamide; Paraneoplastic Syndromes; Phenylurea Compounds; Skin Diseases, Bacterial; Skin Neoplasms; Sorafenib

2016

Trials

36 trial(s) available for clofarabine and cytarabine

ArticleYear
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
    Blood, 2005, Feb-01, Volume: 105, Issue:3

    Topics: Acute Disease; Adenine Nucleotides; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Karyotyping; Leukemia; Male; Middle Aged; Recurrence; Treatment Outcome

2005
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
    Nucleosides, nucleotides & nucleic acids, 2004, Volume: 23, Issue:8-9

    Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cohort Studies; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Models, Chemical; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms; Nucleosides; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome

2004
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
    Blood, 2006, Jul-01, Volume: 108, Issue:1

    Topics: Acute Disease; Adenine Nucleotides; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chromosome Aberrations; Clofarabine; Cytarabine; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome

2006
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Blood, 2008, Sep-01, Volume: 112, Issue:5

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chromosome Aberrations; Clofarabine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Survival Rate

2008
Clofarabine combinations as acute myeloid leukemia salvage therapy.
    Cancer, 2008, Oct-15, Volume: 113, Issue:8

    Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Salvage Therapy

2008
Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
    Bone marrow transplantation, 2009, Volume: 44, Issue:1

    Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous

2009
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
    British journal of haematology, 2010, Volume: 151, Issue:5

    Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Connective Tissue Growth Factor; Cytarabine; Female; Humans; Male; Neoplasm Proteins; Nucleoside Transport Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Treatment Outcome

2010
Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
    The oncologist, 2011, Volume: 16, Issue:2

    Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome

2011
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-20, Volume: 29, Issue:24

    Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Benzenesulfonates; Child; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib

2011
Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome.
    European journal of haematology, 2012, Volume: 88, Issue:1

    Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycophenolic Acid; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous

2012
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
    Cancer, 2012, Sep-15, Volume: 118, Issue:18

    Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Consolidation Chemotherapy; Cytarabine; Decitabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome

2012
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-10, Volume: 30, Issue:20

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Placebos; Recurrence

2012
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
    Haematologica, 2013, Volume: 98, Issue:1

    Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult

2013
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-10, Volume: 30, Issue:32

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Gemtuzumab; Humans; Immunotoxins; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Odds Ratio; Remission Induction; Secondary Prevention; Treatment Outcome

2012
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
    American journal of hematology, 2012, Volume: 87, Issue:12

    Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult

2012
Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
    Pediatric blood & cancer, 2013, Volume: 60, Issue:7

    Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Young Adult

2013
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
    Blood, 2013, Aug-22, Volume: 122, Issue:8

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Remission Induction; Treatment Outcome

2013
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
    American journal of hematology, 2013, Volume: 88, Issue:11

    Topics: Adenine Nucleotides; Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Drug Eruptions; Follow-Up Studies; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Nausea; Pilot Projects; Remission Induction; Survival Analysis; Young Adult

2013
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.
    Annals of hematology, 2014, Volume: 93, Issue:1

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Comorbidity; Cytarabine; Drug Eruptions; Female; Humans; Leukemia, Myeloid, Acute; Liver Failure; Male; Mucositis; Prospective Studies; Remission Induction

2014
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
    British journal of haematology, 2014, Volume: 165, Issue:4

    Topics: Adenine Nucleotides; Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Clofarabine; Cytarabine; Febrile Neutropenia; Female; Heart Arrest; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Risk; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Young Adult

2014
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p
    Annals of hematology, 2014, Volume: 93, Issue:6

    Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Fatigue; Female; Gastrointestinal Diseases; Humans; Hydroxyurea; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Treatment Outcome

2014
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
    Cancer, 2014, Aug-15, Volume: 120, Issue:16

    Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Young Adult

2014
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
    American journal of hematology, 2015, Volume: 90, Issue:4

    Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Young Adult

2015
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Cancer, 2015, Jul-15, Volume: 121, Issue:14

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Remission Induction; Treatment Outcome

2015
A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.
    British journal of haematology, 2015, Volume: 170, Issue:3

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate

2015
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:1

    Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate

2016
Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:7

    Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cohort Studies; Cord Blood Stem Cell Transplantation; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Young Adult

2016
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
    Cancer, 2017, Feb-15, Volume: 123, Issue:4

    Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms; Treatment Outcome

2017
Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC
    Haematologica, 2017, Volume: 102, Issue:2

    Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Random Allocation; Remission Induction; Risk Factors; Survival Analysis; Transplantation, Homologous; Treatment Outcome

2017
Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11

    Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome

2017
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
    Cancer, 2017, Nov-15, Volume: 123, Issue:22

    Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine; Young Adult

2017
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult

2018
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).
    British journal of haematology, 2018, Volume: 183, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction

2018
Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia.
    Echocardiography (Mount Kisco, N.Y.), 2019, Volume: 36, Issue:11

    Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cardiotoxicity; Clofarabine; Cytarabine; Daunorubicin; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left

2019
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acut
    Haematologica, 2022, 05-01, Volume: 107, Issue:5

    Topics: Acute Disease; Antineoplastic Agents; Child; Clofarabine; Cytarabine; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome

2022
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
    British journal of haematology, 2022, Volume: 198, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Clofarabine; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; United Kingdom; Vidarabine

2022

Other Studies

50 other study(ies) available for clofarabine and cytarabine

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Activation of deoxycytidine kinase by various nucleoside analogues.
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Adenine Nucleotides; Antimetabolites, Antineoplastic; Arabinonucleosides; Cell Cycle; Cells, Cultured; Cladribine; Clofarabine; Cytarabine; Deoxycytidine Kinase; Enzyme Activation; HL-60 Cells; Humans; Leukemia; Lymphocytes; Palatine Tonsil; Thymidine Kinase; Tumor Cells, Cultured; Vidarabine

1998
Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study.
    Medical oncology (Northwood, London, England), 1999, Volume: 16, Issue:4

    Topics: Adenine Nucleotides; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Autoradiography; Brain; Cladribine; Clofarabine; Cytarabine; Lipid Metabolism; Mice; Mice, Inbred C57BL; Thymus Gland; Tissue Distribution; Tritium; Vidarabine

1999
New designs for phase 2 clinical trials.
    Blood, 2003, Jul-15, Volume: 102, Issue:2

    Topics: Acute Disease; Adenine Nucleotides; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bayes Theorem; Bias; Biomarkers; Clinical Trials, Phase II as Topic; Clofarabine; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Drug Carriers; False Negative Reactions; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Middle Aged; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Thalidomide; Topotecan; Treatment Outcome

2003
Biochemical modulation of cytarabine triphosphate by clofarabine.
    Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:4

    Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Colony-Forming Units Assay; Cytarabine; Humans; K562 Cells; Maximum Tolerated Dose; Phosphorylation; Ribonucleotide Reductases; Time Factors

2005
The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report.
    Chemotherapy, 2008, Volume: 54, Issue:2

    Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Clofarabine; Cytarabine; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Secondary Prevention

2008
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
    Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11

    Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin

2008
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia.
    American journal of hematology, 2009, Volume: 84, Issue:12

    Topics: Adenine Nucleotides; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Asparaginase; Bone Marrow; Bone Marrow Transplantation; Clofarabine; Combined Modality Therapy; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Transplantation, Homologous; Treatment Outcome; Vincristine; Young Adult

2009
Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:12

    Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome

2009
Last exit clofarabine?
    Leukemia & lymphoma, 2009, Volume: 50, Issue:12

    Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclophosphamide; Cytarabine; Humans; Leukemia; Leukemia, Myeloid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome

2009
Ulcerated plaque under a ruby ring in an immunosuppressed patient.
    Dermatology online journal, 2010, Aug-15, Volume: 16, Issue:8

    Topics: Adenine Nucleotides; Aged; Antineoplastic Agents; Arabinonucleosides; Candida; Candidiasis, Cutaneous; Clofarabine; Cytarabine; Dermatologic Agents; Dermatomycoses; Fusarium; Humans; Immunocompromised Host; Itraconazole; Jewelry; Leukemia, Myeloid, Acute; Male; Pyrimidines; Skin Ulcer; Treatment Outcome; Triazoles; Voriconazole

2010
Successful management with clofarabine for refractory leukaemia in a young adult with chronic renal failure.
    American journal of hematology, 2011, Volume: 86, Issue:3

    Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease Management; Humans; Kidney Failure, Chronic; Leukemia; Male; Renal Dialysis; Salvage Therapy; Treatment Outcome; Young Adult

2011
Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
    Annals of hematology, 2011, Volume: 90, Issue:11

    Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult

2011
Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine.
    Leukemia research, 2011, Volume: 35, Issue:9

    Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Infections; Leukemia, Myeloid, Acute; Recurrence; Treatment Failure

2011
Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia.
    Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:1

    Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Retrospective Studies; Transplantation, Homologous

2012
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
    Blood, 2011, Sep-01, Volume: 118, Issue:9

    Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom

2011
Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012, Volume: 53, Issue:2

    Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Cell Line, Tumor; Clofarabine; Cytarabine; Cytidine Deaminase; Cytosine; Deoxycytidine; Deoxycytidine Kinase; Fluorine Radioisotopes; Gemcitabine; Gene Expression Regulation, Neoplastic; Leukemia, Lymphoid; Mice; Positron-Emission Tomography; Treatment Outcome

2012
Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience.
    American journal of hematology, 2012, Volume: 87, Issue:6

    Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclophosphamide; Cytarabine; Drug Evaluation; Etoposide; Female; Humans; Male; Middle Aged; Off-Label Use; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Salvage Therapy; Spain; Young Adult

2012
Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
    Pediatric blood & cancer, 2012, Dec-15, Volume: 59, Issue:7

    Topics: Adenine Nucleotides; Adolescent; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Line, Tumor; Child; Child, Preschool; Clofarabine; Cytarabine; DNA Damage; Drug Screening Assays, Antitumor; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Infant; Leukemia, Myeloid, Acute; Male; Tumor Cells, Cultured; Valproic Acid

2012
Drug shortages delay cancer clinical trials.
    Journal of the National Cancer Institute, 2012, Jun-20, Volume: 104, Issue:12

    Topics: Adenine Nucleotides; Aged; Antineoplastic Agents; Arabinonucleosides; Child; Clinical Trials as Topic; Clofarabine; Cytarabine; Daunorubicin; Drug Approval; Drug Industry; Drugs, Generic; Europe; Humans; Leukemia, Myeloid, Acute; National Cancer Institute (U.S.); Patient Selection; Survival Analysis; Time Factors; United States; United States Food and Drug Administration

2012
Fatal palmar-plantar erythrodysesthesia after clofarabine and cytarabine chemotherapy.
    Acta haematologica, 2012, Volume: 128, Issue:3

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Fatal Outcome; Hand-Foot Syndrome; Humans; Leukemia, Myeloid, Acute

2012
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
    BMC pharmacology & toxicology, 2013, Jun-15, Volume: 14

    Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases

2013
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:1

    Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Clofarabine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Young Adult

2014
Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.
    Anticancer research, 2014, Volume: 34, Issue:4

    Topics: Adenine Nucleotides; Antimetabolites, Antineoplastic; Apoptosis; Arabinonucleosides; Cell Line, Tumor; Cell Proliferation; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; HL-60 Cells; Humans; Intracellular Space; Leukemia, Myeloid, Acute; Membrane Transport Proteins; Phosphotransferases (Alcohol Group Acceptor)

2014
Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:2

    Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Skin Diseases

2014
How I treat Langerhans cell histiocytosis.
    Blood, 2015, Jul-02, Volume: 126, Issue:1

    Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Clofarabine; Cytarabine; Female; Histiocytosis, Langerhans-Cell; Humans; Infant; Infant, Newborn; Lung Diseases; Male; Middle Aged; Remission Induction; Skin Diseases; Thoracic Surgery, Video-Assisted; Vaginal Diseases

2015
The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:14

    Topics: Acid Anhydride Hydrolases; Adenine Nucleotides; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; Infant; Inhibitory Concentration 50; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Tumor Cells, Cultured

2015
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
    Clinical lymphoma, myeloma & leukemia, 2016, Volume: 16, Issue:3

    Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cohort Studies; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retreatment; Treatment Outcome

2016
The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
    International journal of hematology, 2016, Volume: 103, Issue:5

    Topics: Adenine Nucleotides; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Child; Cladribine; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine

2016
Simultaneous determination of clofarabine and cytarabine in human plasma by LC-MS/MS.
    Journal of pharmaceutical and biomedical analysis, 2016, Jun-05, Volume: 125

    Topics: Adenine Nucleotides; Arabinonucleosides; Chromatography, Liquid; Clofarabine; Cytarabine; Humans; Limit of Detection; Reproducibility of Results; Tandem Mass Spectrometry

2016
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
    Leukemia, 2017, Volume: 31, Issue:2

    Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cause of Death; Clofarabine; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Treatment Outcome

2017
Clofarabine-based consolidation therapy in AML.
    The Lancet. Oncology, 2017, Volume: 18, Issue:4

    Topics: Adenine Nucleotides; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Disease Progression; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Young Adult

2017
Recurrent urinary tract infections and low secretory IgA following CD19-directed CAR T-cell therapy for relapsed acute lymphoblastic leukemia.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:1

    Topics: Antigens, CD19; Antimetabolites, Antineoplastic; B-Lymphocytes; Bacteriuria; Child; Clofarabine; Cytarabine; Escherichia coli; Escherichia coli Infections; Female; Humans; Immunoglobulin A, Secretory; Immunoglobulin G; Immunoglobulin M; Immunotherapy, Adoptive; Lymphocyte Count; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteus Infections; Proteus mirabilis; Urinary Tract Infections

2018
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
    Cancer, 2017, 12-15, Volume: 123, Issue:24

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Clofarabine; Cytarabine; Deoxyadenosines; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Proteins; Vidarabine

2017
Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy.
    Journal of chemotherapy (Florence, Italy), 2018, Volume: 30, Issue:1

    Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult

2018
Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
    Annals of hematology, 2018, Volume: 97, Issue:4

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Case-Control Studies; Chemical and Drug Induced Liver Injury; Clofarabine; Cohort Studies; Combined Modality Therapy; Cost Savings; Costs and Cost Analysis; Cytarabine; Granulocyte Colony-Stimulating Factor; Hospital Costs; Humans; Incidence; Induction Chemotherapy; Length of Stay; Leukemia, Myeloid, Acute; Michigan; Middle Aged; Neutropenia; Propensity Score; Retrospective Studies; Survival Analysis; Tertiary Care Centers; Vidarabine

2018
A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:10

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Minnesota; Progression-Free Survival; Remission Induction; Retrospective Studies; Salvage Therapy

2018
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 06-20, Volume: 36, Issue:18

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine

2018
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.
    Leukemia, 2018, Volume: 32, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; United Kingdom; Vidarabine; Young Adult

2018
Chemotherapy-induced skin toxicity and capillary leak syndrome.
    International journal of dermatology, 2019, Volume: 58, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Clofarabine; Cytarabine; Erythema; Female; Humans; Leukemia; Male; Middle Aged; Skin; Stevens-Johnson Syndrome

2019
Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study.
    British journal of haematology, 2019, Volume: 187, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Young Adult

2019
Clofarabine and cytarabine for acute myeloid leukaemia.
    The Lancet. Oncology, 2019, Volume: 20, Issue:8

    Topics: Arabinonucleosides; Clofarabine; Cytarabine; Humans; Leukemia, Myeloid, Acute

2019
Delayed-onset effect of clofarabine in the treatment of an adult patient with acute myeloid leukemia.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, Feb-21, Volume: 76, Issue:6

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Cell Count; Bone Marrow; Clofarabine; Cytarabine; Filgrastim; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Time Factors; Treatment Outcome

2019
Combination Therapy With Chemotherapy, Donor Lymphocyte Infusion With Concurrent Blinatumomab in Relapsed/Refractory Acute Precursor B-Lymphoblastic Leukemia.
    Journal of pediatric hematology/oncology, 2021, 03-01, Volume: 43, Issue:2

    Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Blood Donors; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Humans; Infant; Lymphocyte Transfusion; Male; Neoplasm Recurrence, Local; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies

2021
Exploring two-dimensional graphene and boron-nitride as potential nanocarriers for cytarabine and clofarabine anti-cancer drugs.
    Computational biology and chemistry, 2020, Volume: 88

    Topics: Antimetabolites, Antineoplastic; Boron Compounds; Clofarabine; Cytarabine; Density Functional Theory; Drug Carriers; Graphite; Humans; Nanoparticles

2020
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
    BMC cancer, 2020, Oct-12, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Clofarabine; Cytarabine; Flavonoids; Humans; Leukemia, Myeloid, Acute; Piperidines; Sulfonamides

2020
The global challenge of treating disseminated LCH.
    Pediatric hematology and oncology, 2020, Volume: 37, Issue:8

    Topics: Antineoplastic Agents; Child; Cladribine; Clofarabine; Cytarabine; Disease Management; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Incidence; Pediatrics; Protein Kinase Inhibitors

2020
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
    American journal of hematology, 2021, 08-01, Volume: 96, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clofarabine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nucleophosmin; Treatment Outcome

2021